Cargando…
Challenges in synthesising cost-effectiveness estimates
Economic evaluations help decision-makers faced with tough decisions on how to allocate resources. Systematic reviews of economic evaluations are useful as they allow readers to assess whether interventions have been demonstrated to be cost effective, the uncertainty in the evidence base, and key li...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727163/ https://www.ncbi.nlm.nih.gov/pubmed/33298168 http://dx.doi.org/10.1186/s13643-020-01536-x |
_version_ | 1783621044997718016 |
---|---|
author | Shields, Gemma E. Elvidge, Jamie |
author_facet | Shields, Gemma E. Elvidge, Jamie |
author_sort | Shields, Gemma E. |
collection | PubMed |
description | Economic evaluations help decision-makers faced with tough decisions on how to allocate resources. Systematic reviews of economic evaluations are useful as they allow readers to assess whether interventions have been demonstrated to be cost effective, the uncertainty in the evidence base, and key limitations or gaps in the evidence base. The synthesis of systematic reviews of economic evaluations commonly takes a narrative approach whereas a meta-analysis is common step for reviews of clinical evidence (e.g. effectiveness or adverse event outcomes). As they are common objectives in other reviews, readers may query why a synthesis has not been attempted for economic outcomes. However, a meta-analysis of incremental cost-effectiveness ratios, costs, or health benefits (including quality-adjusted life years) is fraught with issues largely due to heterogeneity across study designs and methods and further practical challenges. Therefore, meta-analysis is rarely feasible or robust. This commentary outlines these issues, supported by examples from the literature, to support researchers and reviewers considering systematic review of economic evidence. |
format | Online Article Text |
id | pubmed-7727163 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77271632020-12-10 Challenges in synthesising cost-effectiveness estimates Shields, Gemma E. Elvidge, Jamie Syst Rev Commentary Economic evaluations help decision-makers faced with tough decisions on how to allocate resources. Systematic reviews of economic evaluations are useful as they allow readers to assess whether interventions have been demonstrated to be cost effective, the uncertainty in the evidence base, and key limitations or gaps in the evidence base. The synthesis of systematic reviews of economic evaluations commonly takes a narrative approach whereas a meta-analysis is common step for reviews of clinical evidence (e.g. effectiveness or adverse event outcomes). As they are common objectives in other reviews, readers may query why a synthesis has not been attempted for economic outcomes. However, a meta-analysis of incremental cost-effectiveness ratios, costs, or health benefits (including quality-adjusted life years) is fraught with issues largely due to heterogeneity across study designs and methods and further practical challenges. Therefore, meta-analysis is rarely feasible or robust. This commentary outlines these issues, supported by examples from the literature, to support researchers and reviewers considering systematic review of economic evidence. BioMed Central 2020-12-09 /pmc/articles/PMC7727163/ /pubmed/33298168 http://dx.doi.org/10.1186/s13643-020-01536-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Commentary Shields, Gemma E. Elvidge, Jamie Challenges in synthesising cost-effectiveness estimates |
title | Challenges in synthesising cost-effectiveness estimates |
title_full | Challenges in synthesising cost-effectiveness estimates |
title_fullStr | Challenges in synthesising cost-effectiveness estimates |
title_full_unstemmed | Challenges in synthesising cost-effectiveness estimates |
title_short | Challenges in synthesising cost-effectiveness estimates |
title_sort | challenges in synthesising cost-effectiveness estimates |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727163/ https://www.ncbi.nlm.nih.gov/pubmed/33298168 http://dx.doi.org/10.1186/s13643-020-01536-x |
work_keys_str_mv | AT shieldsgemmae challengesinsynthesisingcosteffectivenessestimates AT elvidgejamie challengesinsynthesisingcosteffectivenessestimates |